^
Association details:
| Biomarker: | PD-L1 overexpression |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Jemperli (dostarlimab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
6647 / 19 - Dostarlimab shows dose-dependent immune activation of the tumor microenvironment in a patient-derived NSCLC explant model similar to pembrolizumab
Published date:
03/15/2023
Excerpt:
When testing anti-PD-1 agents, such as dostarlimab and pembrolizumab, in a cohort of NSCLC explants from stage I-III treatment-naïve patients...Interestingly, responsive tumors presented with a high level of PD-L1 expression (high TPS), had elevated TMB...
